Latest news about Transgene Biotek
Transgene Biotek
3.03
+0.08(+2.71%)
Company Performance:
View Company Insights1D+2.71%
1M-0.98%
6M+7.07%
1Y-29.53%
5Y-35.53%
More news about Transgene Biotek
14Apr 26
Transgene Biotek Limited Confirms Non-Applicability of SEBI Regulation 57 for Q4 FY26
Transgene Biotek Limited has filed a compliance notification with BSE confirming that SEBI LODR Regulation 57 does not apply to the company for Q4 FY26. The non-applicability is due to the company not having issued any non-convertible securities, thereby exempting it from related interest, dividend, or principal payment obligations during the quarter.
13Apr 26
Transgene Biotek Limited Files Compliance Certificate for Share Transfer Facility with BSE
Transgene Biotek Limited filed a compliance certificate with BSE on April 13, 2026, under SEBI LODR Regulation 7(3) confirming maintenance of share transfer facilities. The company's registrar and share transfer agent, Bigshare Services Private Limited (SEBI Registration: INR000001385), handles both physical and electronic share transfers. This routine regulatory filing ensures compliance with mandatory disclosure requirements for listed entities.
13Feb 26
Transgene Biotek Limited Reports Q3 FY26 Net Loss of ₹37.38 Lakhs
Transgene Biotek Limited reported a net loss of ₹37.38 lakhs for Q3 FY26 ended December 31, 2025, significantly higher than the ₹8.90 lakhs loss in Q3 FY25. Revenue from operations declined 28.76% to ₹5.45 lakhs, while total expenses more than doubled to ₹42.82 lakhs, primarily due to finance costs surging to ₹27.35 lakhs. For the nine-month period, the company posted a loss of ₹119.59 lakhs against a profit of ₹3.70 lakhs in the previous year.
03Feb 26
Transgene Biotech Limited Faces SEBI Recovery Proceedings Over Rs.38 Lacs Penalty Default
Transgene Biotech Limited has disclosed receiving SEBI's prohibitory order RRD/SRO/1166/2026/1 for recovery of Rs.38 lacs penalty from a June 27, 2022 adjudication order. The order has frozen all bank accounts and prohibited disposal of company assets, causing complete operational paralysis including salary payment suspension. Despite having filed an appeal with Securities Appellate Tribunal on October 7, 2022, which remains pending, the recovery proceedings have brought all business activities to a standstill.
14Nov 25
Transgene Biotek Reports Net Loss and Approves Key Board Decisions
Transgene Biotek Limited reported a net loss of Rs. 38.84 lakhs for Q2 FY2026 ending September 30, 2025, with revenue of Rs. 5.28 lakhs and expenses of Rs. 44.12 lakhs. The company's 35th AGM is scheduled for December 30, 2025. The board approved reappointments of key directors, including Dr. K. Koteswara Rao as Chairman & Managing Director. Ongoing legal challenges include hearings at SAT Mumbai and Appellate Tribunal New Delhi, and an appeal at NCLT Hyderabad.
17Oct 25
Transgene Biotek Faces Legal Challenge at NCLT Over Rs 6.82 Crore Unpaid Loan
Transgene Biotek, a biotechnology company in Telangana, India, is facing a legal case at the NCLT Hyderabad Bench. Babaji Nethralayya Private Ltd has filed a case for an unpaid loan of Rs 6.82 crore plus interest. The company acknowledged the proceedings in a BSE filing and stated efforts are being made to resolve the matter amicably. The next hearing is scheduled for December 16, 2025.
07Aug 25
Transgene Biotek Reports Q1 Loss, Appoints New Auditors Amid Ongoing Regulatory Challenges
Transgene Biotek Limited reported a net loss of Rs 43.37 lakhs in Q1, compared to a profit of Rs 19.94 lakhs in the same period last year. Revenue from operations slightly increased to Rs 4.95 lakhs. The company appointed new Internal and Secretarial Auditors. Regulatory challenges persist, with ongoing proceedings at the Securities Appellate Tribunal and Appellate Tribunal in New Delhi. The company cleared the principal sum owed to BIRAC but faces operational difficulties due to regulatory issues.
Industry Peers
Dr. Lal Path Labs
Vijaya Diagnostic Centre
Metropolis Healthcare
Thyrocare Technologies
Nephrocare Health Services
Krsnaa Diagnostics
One Global Service Provider
Suraksha Diagnostic
Health X Platform
3B BlackBio DX
1,660.00
(-0.57%)
1,312.60
(+1.39%)
553.20
(+1.83%)
555.80
(-0.47%)
679.75
(-1.51%)
537.55
(+0.80%)
751.15
(+4.95%)
271.90
(-1.41%)
323.05
(+1.62%)
1,170.50
(-0.90%)
we are part of Raise Financial Services
built with love
for indians who love to invest & trade
Market Community
Follow us on
